This observation suggests that ovarian carcinomas with mutations in either KRAS or BRAF are more highly dependent on the activation of the RAS–RAF–MEK–ERK pathway for cell proliferation and survival than those without such mutations. The gene discussed is KRAS; the disease is ovarian carcinoma.